Five participants gain cognitive benefits after receiving intranasal gene therapy
– CEO of BioViva USA Inc, Liz Parrish
SEATTLE, WA, UNITED STATES, November 11, 2021 /EINPresswire.com/ – In a sponsored safety study, the first of its kind, five patients with mild to moderate dementia received proprietary intranasal dual gene therapy consisting of hTERT and Klotho. The the conclusions of the study were published this month in volume 3 of the refereed Journal of Regenerative Biology and Medicine; Number 6 (2021).
The study was primarily structured for safety. The treatment demonstrated an excellent safety profile without complications. Efficacy data was also collected and monitored, including immune system response, physical exams, telomere length, blood tests, and brain imaging.
The beneficial effects of the treatment were demonstrated by a sustained improvement in the score on the Folstein exam, a test used to measure cognitive impairment. The improvement in the Folstein score corresponds to an improvement in memory and cognition. “This is a remarkable study given that cognitive function in patients with dementia predictably declines every year. Without treatment, a patient’s Folstein test score declines by about 3 points per year afterwards. the diagnosis, âsaid Patrick Sewell, director of clinical affairs for BioViva. .
Systemic telomere lengthening was observed in all patients. Longer telomeres have been associated with a reduced risk of a myriad of age-related diseases and all-cause mortality. Telomere lengthening leads to longer replicative cell life and is associated with younger biological age.
âTelomere shortening and reduced Klotho expression are directly correlated with diseases of aging,â said Elizabeth Parrish, CEO of BioViva, âthis study demonstrates the potential to successfully treat aging at the cellular level. ‘Efforts and billions of dollars spent in researching dementia, we have seen very little progress … until now. Anyone who has lost a loved one to dementia understands the importance of this work. ”
The patent-pending study was performed by Integrated Health Systems and was sponsored by Maximum Life Foundation, a 501 (c) (3) organization; BioViva USA Inc. evaluated the results.
About BioViva USA Inc.
BioViva USA Inc. is a company dedicated to the evaluation and development of gene therapies and novel viral vectors to treat diseases associated with aging.
Contact: [email protected]
About Integrated Health Systems Ltd.
IHS is an international consortium of medical specialists qualified to create and deliver cutting-edge and tailor-made regenerative therapies.
Contact [email protected]
Companion video: Human dementia study: BioViva analyzes the data